Part 4 of 4: Jon Chee hosts Chris Moxham, Co-Founder, CEO, and CSO of Transcripta Bio—a pioneering biotech company accelerating drug discovery to improve lives worldwide.
With a PhD in Molecular and Cellular Pharmacology from Stony Brook University and over 25 years in drug discovery, Chris brings a wealth of experience. During his two-decade tenure at Eli Lilly, he advanced over 10 molecules into clinical trials across multiple therapeutic areas, spanning both small and large molecule modalities.
Chris’s deep expertise and dedication to scientific innovation and team development offer invaluable insights for aspiring biotech leaders.
Join us this week to hear about:- The complexities of building partnerships with Big Pharma as a startup
- Insights on developing relationships with larger organizations and patient foundations
- The importance of mutual goals and the art of aligning incentivesÂ
- Transcripta’s progress with their groundbreaking Drug-Gene Atlas, combining genetics, AI, and high-throughput data to redefine the future of drug discovery
Please enjoy Jon’s conversation with Chris Moxham.
Subscribe to the podcast: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994
Find Our Guest, Chris Moxham, at these links:Â https://www.linkedin.com/in/christopher-moxham-b8867011/Â https://www.transcriptabio.com/Â
Find Our Host, Jon Chee, at these links:Â https://www.linkedin.com/in/joncheehttps://www.excedr.com
Excedr Socials & WebsiteLinkedIn: https://www.linkedin.com/company/excedr/ Youtube: https://www.youtube.com/@excedr Instagram: https://www.instagram.com/excedr_inc Twitter: https://twitter.com/ExcedrInc Facebook: https://www.facebook.com/excedr TikTok: https://www.tiktok.com/@excedr Podcast Website: https://www.thebiotechstartupspodcast.com/
Enriched Notes:Â
Topics Mentioned:Eli Lilly & Company: https://www.lilly.com/Transcripta Bio: https://www.transcriptabio.com/Fulcrum Therapeutics: https://www.fulcrumtx.com/NVIDIA: https://www.nvidia.com/en-us/Biotech Partnerships with Big Pharma: https://www.excedr.com/blog/how-biotech-partnerships-support-researchThe Role of BD in the Life Sciences: https://www.excedr.com/resources/business-development-in-the-life-sciencesHow to Break into Biotech BD: https://www.excedr.com/blog/how-to-break-into-biotech-bd-as-a-phd-studentDrug-Gene Atlas: https://www.transcriptabio.com/what-we-doBiotech Startup Support: https://www.excedr.com/resources-category/biotech-startup-support
People Mentioned:Efraim Racker: https://efraimracker.library.cornell.edu/Craig Malbon: https://www.pharm.stonybrook.edu/faculty/m/malbonJohn Hadcock: https://www.linkedin.com/in/hadcock/Alan Palkowitz: https://www.linkedin.com/in/alan-palkowitz-7387653/Phil Hipskin: https://www.linkedin.com/in/philip-hipskind-a3b11611/Greg Plowman: https://www.linkedin.com/in/greg-plowman-4177096/Robert Gould: https://www.linkedin.com/in/robertjgouldfulcrum/Jim Collins: https://be.mit.edu/faculty/james-j-collins/Jim Geraghty: https://www.linkedin.com/in/jim-geraghty-7481a262/Alan Ezekowitz: https://www.linkedin.com/in/alan-ezekowitz-54030515/Dave Port: https://www.linkedin.com/in/j-david-port-ab9616b/
Timestamps:00:00 Intro and recap02:09 Partnering with Big Pharma and the urgency of startups04:13 Learning business development and building successful partnerships06:18 Understanding stakeholder involvement and approval layers in Big Pharma09:42 Transcripta's collaborations with patient foundations and medical institutions11:31 Ideal partnerships with academic institutions and aligning incentives15:53 The importance of partnership alignment, building trust within the org20:47 Transcripta Bio's vision for the future21:52 Shoutouts and advice to younger self24:45 OutroThe Biotech Startups Podcast gives you a front-row seat to the business
and science of building a biotech. Hosted by Jon Chee, CEO of Excedr, the show features honest conversations with founders, execs, and investors about their work, their companies, and how they got there. From scientific breakthroughs to startup lessons, each episode explores what it really takes to grow a life science company—from pre-seed to IPO.